Showing 1 - 9 results of 9 for search 'Earls of Lade~', query time: 0.93s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Autophagy Mediates MMP-2 Expression in Glaucomatous Trabecular Meshwork Cells by Yan-Ling Xiao, Xiao-Rui Wang, Kejing Ye, Wan-Zhu Chen, Bing-Ru Zheng, Yi-Hong Huang, Yu-Yu Wu

    Published 2022-01-01
    “…Compared to the control group, starvation significantly upregulated LC3-II and Beclin1 in TM cells after 3 h of stimulation, which peaked at 6 h and 9 h, respectively. Increased MDC-labeled cells were also observed. Starvation downregulated the expression of MMP-2. …”
    Get full text
    Article
  5. 5

    A Reader in Promoting Public Health : challenge and controversy /

    Published 2010
    View in OPAC
    Book
  6. 6

    Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation by Vera V, Sheybani A, Panarelli JF, Grover DS, Lee J, Craven ER, Samuelson TW, Ahmed IIK

    Published 2025-01-01
    “…Vanessa Vera,1 Arsham Sheybani,2 Joseph F Panarelli,3 Davinder S Grover,4 James Lee,5 Earl Randy Craven,2 Thomas W Samuelson,6 Iqbal Ike K Ahmed7 1Allergan, an AbbVie company, Irvine, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3Department of Ophthalmology, New York University Langone Health, New York, NY, USA; 4Glaucoma Associates of Texas, Dallas, TX, USA; 5Colorado Eye Institute, Colorado Springs, CO, USA; 6Minnesota Eye Consultants, University of Minnesota, Minneapolis, MN, USA; 7John Moran Eye Center, University of Utah, Salt Lake City, UT, USACorrespondence: James Lee, Colorado Eye Institute, Colorado Springs, CO, 80924, USA, Email jlee@eyescolorado.comAbstract: The XEN® 45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. …”
    Get full text
    Article
  7. 7
  8. 8
  9. 9